Insufficient angiogenesis remains a major hurdle in current bone tissue engineering strategies.
Introduction
Current bone regeneration approaches still face a wide range of limitations that in combination to the increased incidence of bone pathologies linked to the general population aging profile it continues to pose an important health challenge. Present regeneration approaches are focused on three main strategies: 1) autologous bone grafts that, although the gold standard for bone regeneration and the most common approach, implies a two stage time consuming surgical procedure, that requires patients in general good health and is often associated with significant morbidity, post-operative pain, hypersensitivity, infection and paresthesia [1] [2] [3] [4] ; 2) allogeneic bone grafts, often associated with immunogenic and infection risks [5] ; and 3) bone substitutes, based on biodegradable polymers and/or synthetic ceramics, increasingly being studied as bone tissue engineering material as they can be established as an off-the-shelf clinical product [6] .
This last approach, although with great potential to satisfy clinical need, has shown insufficient vascularization and osteointegration, when in the absence of autologous cells and/or proangiogenic factors [7] . Indeed, attempts to stimulate neovascularization, by the use of recombinant protein, angiogenic growth factors gene transfer or endothelial cells have been proposed, however often associated with problems regarding the delivery and duration of exposure to the growth factors and with the survival of endothelial cells [7] . Additionally, due to inherent risks, the use of growth factors and autologous cells presents additional regulatory hurdles, particularly relevant in some cases of bone repair post cancer resection [8] . Hence, in order to fulfill the promise of bone tissue engineering the problematic of neovascularization, inside the implanted constructs, has to be solved in order to reach the bedside. This drawback is particularly relevant in large bone defects, where the amount of oxygen required for cell survival is limited to a diffusion distance between 150-200 µm from the supplying blood vessels [9] . Nonetheless, in view of a broad clinical application, the establishment of off-the-shelf strategies may prove beneficial and reduce regulatory issues. As such, the use of synthetic polymeric matrices, that can be readily engineered and custom designed, may show the future for new bone therapeutic approaches.
We have recently demonstrated the potential of electrospun poly(lactic acid) (PLA) fiber-based membranes, containing calcium phosphate ormoglass (CaP) particles, to elicit angiogenesis in vivo, in a subcutaneous model in mice [10] . These CaP particles with capacity to release bioactive calcium ions, in a controlled fashion, are an alternative cost effective approach in order to achieve ready-to-use bone substitutes. Based on the observation that sudden increased local concentration of calcium (Ca 2+ ) ions could induce the migration, maturation and organization of endothelial progenitors [11] , we could demonstrate in vivo that these materials could elicit the local expression of angiogenic factors, associated to a chemotactic effect on macrophages, and sustain angiogenesis into the biomaterial [10] .
On the other hand, calcium phosphate glass ceramic are a very promising alternative for a more progressive ion release rate as crystalline phases use to degrade slower than glassy ones Here we evaluated the use of a sol-gel prepared CaP glass-ceramic in an orthotopic model, in a condylar defect in rat, to sustain both bone repair and angiogenesis. We tested different calcination temperatures, in order to tune Ca 2+ release profiles, formulated them as an injectable composite and associated it with a PLA/ormoglass contention membrane.
Materials and Methods

Reagents
Unless mentioned otherwise, all reagents were obtained from Sigma-Aldrich and were of analytical grade.
Scaffolds fabrication and characterization
Sol-gel alkoxide precursor solutions were prepared by refluxing them in proper solvents, except
Ti tetraisopropoxide was commercially obtained (ALFA AESAR, 97%) and diluted in absolute ethanol. Ca and Na precursor solutions were prepared by refluxing metallic Ca and Na in 2-methoxyethanol. P precursor solution was obtained by refluxing P2O5 in absolute ethanol.
Electrospun PLA mats with embedded NP
CaP ormoglass NPs were prepared by a partial hydrolyzed alkoxides sol-gel method with a composition of 44.5:44.5:6:5 CaO:P2O5:Na2O:TiO2 molar ratio, following a previous report [12] . After mixing Ca, Na an Ti precursor solutions in the proper molar ratio in inert atmosphere, a catalyst with a composition related to Ti (Ti:H2O:NH3:EtOH 1:60:0.3:12) was added at 4ºC at 2 ml/h using an infusion pump. Afterwards, P precursor was similarly added at 4ºC and 1 ml/h flow. The mix turned from dark brown to clear orange and it was subsequently hold at 70ºC during 4 days for aging and allow the formation of NPs. They were finally collected and washed with absolute ethanol by centrifugation and dried at 90ºC in the oven.
Nanofiber mats were prepared as previously described [10] . Briefly, PLA nanofibers loaded with 20% (w/w) of CaP ormoglasses (labelled as PLA CaP) were prepared by the ultrasonic dispersion of the nanoparticles in a 4% (w/v) PLA (Purasorb PLDL 7038, inherent viscosity midpoint 3.8 dl/g, molecular mass ≈ 850,000 Da) solution. Slurries were electrospun at 8.000V, 150 mm distance tip-collector and at 1200 rpm rotary collector speed.
Nanostructured G8 glass-ceramic injectable gels fabrication
To prepare the glass-ceramic material Ca, Na and Ti precursor solutions were mixed in inert atmosphere in the proper molar ratio, similarly to previous process. P precursor solution was then added at 4ºC and a rate of 2.5 mL/h using an infusion pump. Then, an acid aqueous catalyst with a Ti molar relation of Ti:20 H2O:0. 
Calcium release, FE-SEM characterization and chemical composition.
Calcium release from the glass-ceramics powders was measured using an ion selective Micro-and Nano-morphology was measured using an Ultra-High Resolution Field Emission Scanning Electron Microscopy (Nova Nano SEM-230; FEI Co., Netherlands), operating at 5.00
Kv and coating the samples with an ultra-thin layer of carbon to make them conductive.
Material's composition was assessed using an Energy Dispersive X-ray Spectrometer (EDS, Quanta 200 XTE 325/D8395; FEI Co.). Materials were also coated with a thin layer of carbon before analysis.
Glass transition temperature and simultaneous thermogravimetric (TGA) and differential thermal analysis (DTA).
Glass transition temperature was measured on a Q20 differential scanning calorimeter (TA instruments, USA). A heating rate of 10°C/min to 600°C was used. Simultaneous thermogravimetric and differential thermal analysis of the sol-gel sample was executed on a
Netzsch STA 409 C/CD instrument (NETZSCH-Gerätebau GmbH, Germany). A heating rate of 10°C/min to 900°C was used.
X-ray diffraction
XRD was measured on a PANalytical X'pert PRO MPD Alpha1 powder diffractometer.
Patterns were collected from 2θ = 4.2 to 80° with a step size of 0.017° and a measuring time of 50 seconds per step.
Organic Elemental Analysis
Powder glass-ceramic samples were analyzed after heat treatment to determine residual carbon using a Carlo Erba Instruments Thermo Flash 2000 (Carlo Erba, Milan, Italy). This method is based on a Gas chromatography after total decomposition and oxidation of the sample at high temperature (~1800ºC). For that purpose, 100mg samples were used..
Cell culture
Human progenitor-derived endothelial cells (PDECs) were obtained as previously described [13] . 
In vitro evaluation
Twenty-four hours prior, PDECs were seeded on 24 well plates at 20x10 3 /cm 2 and cultured using 500 μL of endothelial cell growth medium-2 (EGM-2; Lonza-Verviers, France). Then, 50 μL of HPMC gels, containing 40% (w/v) of CaP particles sintered at 540 or 570 degrees, were placed inside a 0.4 μm pore transwell (Corning, EMEA, France) and set in contact with the cell culture medium. At designated time points cells were processed for viability assay or cells culture medium was assessed for VEGF quantification.
Cell viability assessment
Cytotoxicity assessment on human PDECs was performed according to the standard ISO/EN 10993, part 5, guidelines and using the neutral red assay. Briefly, 24 hrs post exposure to the HPMC gels, through the transwell inserts, and the colorimetric neutral red assay was performed according to established protocols [14] .
VEGF secretion evaluation
In order to assess the capacity of the different materials to induce the secretion of vascular endothelial growth factor (VEGF), the cell culture medium of PDECs cultured on the different materials for 4 days was recovered, snap frozen and kept at -80ºC until further use. Secreted VEGF was evaluated by ELISA assay using a commercial kit (human VEGF ELISA, #DVE00, R&D Systems, USA) following the manufacturer's instructions.
Animal procedures
As an initial model to assess the capacity of the developed materials to sustain bone repair we implanted them in a bone defect model in rats, condylar defect. All the procedures for rat inhalation and femoral bones were recovered for histologic, immunohistochemistry and μCT evaluation. Six independent materials were implanted per tested material and per time point.
X-ray microtomography and analysis
Micro-CT was performed on Explore Locus SP X-ray m-CT devices (General Electric, Milwaukee, WI) ex vivo with a source voltage of 80 kV and a current of 60 mA to obtain a 15 mm resolution from 900 X-ray radiographs with an exposure time of 3000 ms. After scanning, cross-sectional slices were reconstructed and three-dimensional analysis were performed using eXplore MicroView software (General Electric Healthcare, Milwaukee, WI). Reconstruction of the region of interest was performed after correction of the center of rotation and calibration of mineral density. Each scan was reconstructed using the same calibration system to distinguish bone and air. Bone volume (BV) per total volume (TV) was determined for each sample.
Histological analysis
The femoral and tibial bones were recovered, fixed with 4% (w/v) paraformaldehyde for 48 hrs at 4°C and then demineralized (Microdec, Diapath, France), dehydrated and embedded in paraffin. Eight microns sections were cut and stained with Masson's Trichrome for osteoid staining, using standard protocols, and observed under a photomicroscope (Nikon eclipse 80i, The Netherlands).
Immunohistochemistry analysis
Immunohistochemistry for CD31 was performed as follows. Eight-micron paraffin sections were cut, deparafinized, rehydrated using ethanol gradients and placed in PBS. Antigen recovery was performed using a proteinase K (Roche, France) digestion procedure and then endogenous peroxidase was quenched using 3% (v/v) hydrogen peroxide for 5 min at room temperature (RT). Tissues were blocked with 2% horse serum, in PBS, for 30 min at RT.
Primary antibody against CD31 (NB100-2284, Novus Biologicals, Bio-Techne, France) was used at 1:100 in 2% (w/v) BSA in PBS, and incubated overnight at 4°C. After two washes with PBS, the anti rabbit Impress kit (VectorLabs, USA) was used according to the manufacturer's instructions. Specific staining was obtained using the 3,3'-diaminobenzidine staining solution (VectorLabs, USA). Counterstaining was performed using Mayer's haematoxylin. Samples were then mounted using Pertex medium (Sigma). Sample imaging was performed using a microscope (Nikon Eclipse 80i) equipped with a digital camera (Nikon Dxm 1200C). Sample analysis was performed at three different sample positions and a total of six animal samples
were assessed per time point and condition. For vessel quantification the total number of micro vessels was determined and normalized to the area of the defect.
Statistical analysis
Using the Graphpad Prism 5.0 software, a D'Agostino and Pearson omnibus normality test was used in order to test if data obeyed to a Gaussian distribution. Statistically significant differences between several groups were analyzed by the non-parametric Kruskal-Wallis test, followed by a Dunns post-test. The non-parametric Mann-Whitney test was used to compare two groups. A p value lower than 0.05 was considered to be statistically significant.
Results
Biomaterial synthesis and characterization
Differential thermal analysis (DTA) is a powerful tool when considering sol-gel glasses analysis, due to the ability to evaluate the chemical changes that occur during the calcination steps. Figure 1A displays the DTA plot for the sol-gel material, and in this representation, exothermic reactions correspond to a downward peak on the y-axis. The gravimetric portion of this plot is characterized by a series of downward steps, as materials are burned away during calcination. These downward steps correspond with peaks in the thermometric plot, signifying a chemical change in the sample. The major events in the sol-gel material include a small mass loss and exothermic peak at around 130°C, which corresponds to the loss of residual water from the material, and then two endothermic peaks at about 250 and 320°C as the organic residues are eliminated. Indeed, and as observed in Table 1 , residual carbon content was below 0.1%, consistent with the DTA results. Additionally, glass transition temperature (Tg) was 480ºC in both cases and composition, measured by energy dispersive X-ray spectroscopy (EDS), was as expected ( Table 1) . In order to analyze the formation of the crystalline phase after the calcination of the sol-gel material, an X-ray powder diffraction (XRD) evaluation was performed. Figure 1B shows how the final amount of crystallization within the material is closely related to the temperature of calcination. Here, all sol-gel samples are compared at the 4 different temperatures treated. Corresponding to the step-wise increase of calcination temperature, each subsequent material exhibits an increase in crystallinity. The sample calcined at 500 ºC had a completely amorphous behavior, and presented a dark grey color associated to a high carbon content. As such, this sample formulation was discarded from further studies.
The one calcined at 540°C still contains a large amorphous phase, while the powder calcined at 
In vitro evaluation
In view of the application of these matrices to bone tissue regeneration and to support angiogenesis we initially tested the influence of the composite biomaterial over human PDECs cell viability. As observed in figure 3A , no significant differences could be observed for both CaP formulations, in relation to the control. Additionally, and as means to assess the impact of the composite formulation over the expression of VEGF we performed an ELISA assay to determine the VEGF secretion by PDECs after 4 days of exposure, using a transwell system.
As observed in figure 3B a significant increase of VEGF secretion was observed for the 540 ºC CaP composite formulation, in relation with the control. Quantification of vascular endothelial growth factor (VEGF) expression by PDECs cultured with exposure, during 4 days, to HPMC gels containing 40% (w/v) of CaP, sintered at 540 or 570 ºC (n=4, average±SD; * and NS denotes p<0.05 or non significant, respectively).
In vivo evaluation
In view of determining the capacity of the developed composites to sustain bone repair we focused on a bone defect model in the rat condyle. For this purpose, the two developed composite injectable hydrogels, based on sintered CaP at 540 or 570 ºC, were placed in the defect and covered with an electropsun PLA membrane (containing or not 20% (w/w) of CaP particles) previously reported [10] . Bone regeneration was evaluated at 3 and 6 weeks postimplantation using micro CT based 3D reconstruction and histologic evaluation. In view of evaluating the impact of the different formulations, containing CaP particles sintered at two distinct temperatures (i.e. 540 and 570 ºC), on the formation of angiogenesis, we performed an immunohistochemistry for CD31 at 3 and 6 weeks post implantation in a rat condylar defect model. As observed in Figure 6 , CD31 immunostaining revealed the existence of vessels inside the defect at both 3 and 6 weeks post implantation. The vessel distribution was homogeneous throughout the defect, being visible both at the center and at the periphery, inside the defect. As means to quantify the influence of both the presence of CaP particles within the composite material and of the CaP sintering temperature on angiogenesis we performed vessel quantification inside the defect. As observed in Figure 7 , and although no significant differences could be observed at 3 weeks, at 6 weeks post implantation a significant increase for vessel density could be observed for the defects implanted with HPMC containing CaP particles sintered at 540ºC and covered with PLA membranes, containing CaP, in relation to HPMC and PLA alone. 
Discussion
Autologous bone grafts are still the gold standard when considering the regeneration of bone defects. Nonetheless, they are associated with several drawbacks, including limited graft availability, increased risk of infection and significant morbidity at the donor site [15] . In this sense bone tissue engineering approaches have been proposed as promising alternatives, but in spite of tremendous effort and important advances achieved in the last two decades they have not yet fulfilled their promise [16] . One of the major problematic associated with the efficient translation of bone tissue engineering is the inefficient vascularization of both the implanted constructs and the defect site [6] . In this regard, growing interest has been focused on the development of bioactive biomaterials that can modulate the angiogenesis process, during bone tissue regeneration. Recently, we have shown the potential of electrospun poly(lactic acid) (PLA) fiber-based membranes, containing calcium phosphate ormoglass (CaP) particles, to elicit angiogenesis in vivo, in a subcutaneous model in mice [10] . In order to apply this principle to a bone regeneration scenario, here we developed a two component biomaterial approach: 1) a contention membrane of electrospun PLA, containing 20% (w/w) of CaP particles, that was previously optimized [10] ; and 2) an injectable gel composed of a new generation of CaP ormoglasses, dispersed at 40% (w/v) in a HPMC gel.
HPMC is a derivate polymer of cellulose that has shown to exhibit suitable biological characteristics and that has already been used for the formulation of injectable biomaterial matrices, containing calcium phosphate ceramics [17] [18] [19] .
Our first approach was to optimize the conditions of CaP particle production, focusing on their ration of glass/ceramic character, in order to tune their degradation rate and obtain a sustained calcium release profile. As expected, a significant mass loss was observed during the first step of calcination, up to 350ºC, where the material lost nearly 40% in terms of mass. These results were in agreement with previous reports of sol-gel synthesis of phosphate glasses [20, 21] , where at 350ºC the vast majority of the water and extraneous organic material can be eliminated, as shown in Table 1 .
The use of different calcination temperatures, over the Tg (Table 1) , shows the appearance of different crystal phases (Figure 1B) , such as pyrophosphates and the polymorph γ of the tricalcium phosphate. These compounds, as well as the notable absence of calcium-phosphates, have shown to be characteristic of phosphate-based sol-gel and melted glasses [22] .
Additionally, the presence of a NaTi2(PO4)3 peak shows that in spite of the small quantity used, an efficient inclusion of both titanium and sodium, into the crystalline network, was achieved.
Also, and although the ratios of these compounds remain similar throughout the heating process, higher processing temperature show to favor the β-calcium pyrophosphate phase. As previously mentioned, the aim was to achieve a blend of both glassy and crystalline CaP ormoglass, as such and due to the high crystallinity of the formulation calcinated at 610ºC, this last was discarded from further studies.
One of the limitations regarding glassy materials resides on their fast degradation, after immersion in fluid, and therefore accelerated release of ions in the first several days, before flattening out to a relatively slow release rate [23] . Conversely, we show that by introducing a nanocrystalline phase we could achieve a constant calcium release rate. This approach allows to tune the release profiles, while maintaining the advantageous zero-order release.
Additionally, and in contrast to glassy calcium phosphates materials that usually exhibit a dramatic and immediate pH drop, due to the burst release mechanism [23] , our approach shows little pH variation, over the entire time course. This presents an added value for these materials as significant acidifications has shown to induce osteoblast cell death and pro-inflammatory cytokine release by osteoblastic cells [24] .
Nonetheless, the thermic process used, necessary to eliminate organics and nucleate the crystal nanophases, shows particle sintering due to the high atomic diffusion. Alternative processes can be used to avoid this issue such as the modification of the thermodynamic stability by altering some experimental conditions or using methods such as spray pyrolysis to avoid the physical contact among particles during the phase's growth.
Following the establishment of two ormoglass formulations, calcined at 540 and 570ºC, and based on previous reports [18, 19] , we formulated them at 40% (w/v) in a 2% (w/v) HPMC gel.
In vitro tests confirm their lack of toxicity for PDECs, under the test conditions, and show a dependence of the calcination temperature on their capacity to elicit VEGF secretion. The HPMC gels containing 40% (w/v) of CaP, sintered at 540 showed the better performance in terms of VEGF secretion. This correlates well with our previous studies were it was demonstrated that Ca 2+ release from ormoglass particles, in the range of 0.6 -1 mM, induced expression of VEGF gene and protein secretion [10, 25] .
Then, focusing on the application of these composites for bone repair we evaluated their capacity to sustain bone repair in a condylar defect model in rat. Significant improvement in terms of BV/TV was observed for the 540 formulation, at 3 weeks, and for both 540 and 570, at 6 weeks, in relation to the vehicle alone. These results are in line with the Ca 2+ release kinetics of both the 540 and 570 formulations, where a faster Ca 2+ release (i.e. 540) shows to favor a faster bone repair, evident by micro CT analysis and by the formation of osteoid tissue. Previous studies have indeed shown that elevated Ca 2+ levels could promote the recruitment of bone marrow progenitor cells in vivo [26, 27] , regulate both bone morphogenetic protein and type I collagen synthesis by osteoblastic cells [28] and modulate the osteoinduction of mesenchymal stem cells [29] . Additionally, we and others have shown that bioactive glasses sustain the expression of proangiogenic cytokines and indirectly induce angiogenesis in vitro [25, 30] and in vivo [10] . The in vitro mechanism of action of these bioactive ormoglasses has been associated with the degradation of the CaP, leading to the release of physiologically relevant amounts of ions in the extracellular media [30] [31] [32] . In vivo, we have recently shown that, correlated with the Ca 2+ release there was a significant expression of angiogenic factors, associated to a chemotactic effect on macrophages, what finally showed a significant increase of angiogenesis into the biomaterial [10] .
As extracellular calcium has shown important roles both on proliferation, chemotaxis and differentiation of cells, and as elevated calcium levels have been described in the extracellular fluids of tissues suffering remodeling [33] , namely bone, it has been proposed that increased calcium levels may act as paracrine regulators for various cellular functions.
Indeed, in the same line of we have recently shown [10] , the injectable composite, containing 40% of ormoglasses cancined at 540ºC, shows a significant improvement in terms of angiogenesis. We assume that due to its faster Ca 2+ release kinetics, in relation to the ormoglasses sintered at 570 ºC, it enables the release of Ca 2+ in a range suitable for both improved osteogenesis and angiogenesis.
Altogether, one can assume that local elevated calcium levels may induce the recruitment of cells able to favor both a pro angiogenic milieu and to sustain bone formation. This approach allows in a simple and cost effective manner to address both the promotion of bone repair and to sustain angiogenesis.
Conclusions
We have developed an injectable composite, containing a CaP glass-ceramic dispersed within a HPMC matrix, with the capacity to release calcium in a controlled way. We show that by tuning the release of calcium, in vivo, we could improve both bone formation and also increase
